CA2520392C - Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding - Google Patents

Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding Download PDF

Info

Publication number
CA2520392C
CA2520392C CA2520392A CA2520392A CA2520392C CA 2520392 C CA2520392 C CA 2520392C CA 2520392 A CA2520392 A CA 2520392A CA 2520392 A CA2520392 A CA 2520392A CA 2520392 C CA2520392 C CA 2520392C
Authority
CA
Canada
Prior art keywords
cal
vip
binding
abs
covalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2520392A
Other languages
English (en)
French (fr)
Other versions
CA2520392A1 (en
Inventor
Sudhir Paul
Yasuhiro Nishiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2520392A1 publication Critical patent/CA2520392A1/en
Application granted granted Critical
Publication of CA2520392C publication Critical patent/CA2520392C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
CA2520392A 2003-03-26 2004-03-26 Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding Expired - Fee Related CA2520392C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45729303P 2003-03-26 2003-03-26
US60/457,293 2003-03-26
PCT/US2004/009399 WO2004087059A2 (en) 2003-03-26 2004-03-26 Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding

Publications (2)

Publication Number Publication Date
CA2520392A1 CA2520392A1 (en) 2004-10-14
CA2520392C true CA2520392C (en) 2014-08-12

Family

ID=33131674

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2520392A Expired - Fee Related CA2520392C (en) 2003-03-26 2004-03-26 Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding

Country Status (5)

Country Link
US (1) US9006388B2 (https=)
EP (1) EP1610808A4 (https=)
JP (2) JP5503837B2 (https=)
CA (1) CA2520392C (https=)
WO (1) WO2004087059A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520381A1 (en) 2003-03-26 2004-10-14 Sudhir Paul Proteolytic and covalent antibodies
WO2004087059A2 (en) 2003-03-26 2004-10-14 The University Of Texas Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding
EP1613643A4 (en) 2003-03-27 2009-10-28 Sudhir Paul LUPUS ANTIBODIES FOR THE PASSIVE IMMUNE THERAPY OF HIV / AIDS
US8617568B2 (en) * 2007-07-10 2013-12-31 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
JP2012501654A (ja) * 2008-09-05 2012-01-26 アビラ セラピューティクス， インコーポレイテッド 不可逆的インヒビターの設計のためのアルゴリズム
NZ620174A (en) * 2009-09-16 2016-08-26 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
EP2519664A4 (en) 2009-12-30 2014-03-12 Avila Therapeutics Inc LIGAND-RELATED COVALENTS MODIFYING A PROTEIN
EP3511424B1 (en) 2012-08-03 2023-10-18 University Of Washington Through Its Center For Commercialization Compositions and methods for improving nanopore sequencing
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952462A (en) 1983-11-29 1999-09-14 Igen International Inc. Transition state analogs
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5695927A (en) 1988-03-31 1997-12-09 The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology Monoclonal antibodies specific for HIV and the hybridomas for production thereof
US5445960A (en) 1988-03-31 1995-08-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Monoclonal antibodies specific for HIV and hybridomas for their production
JP2809533B2 (ja) * 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5801149A (en) * 1991-06-19 1998-09-01 Joslin D-Abetes Center, Inc. Inhibition of signal transduction molecules
WO1993015751A1 (en) * 1992-02-14 1993-08-19 Merck & Co., Inc. CHIMERIC TOXINS BINDING TO THE GnRH RECEPTOR
US5574142A (en) * 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5952307A (en) * 1994-01-21 1999-09-14 Georgia Tech Research Corp. Basic α-aminoalkylphosphonate derivatives
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5543396A (en) * 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
US5916877A (en) * 1994-10-18 1999-06-29 Georgia Tech Research Corporation Fluorescent 1-peptidylaminoalkanephosphonate derivatives
US6156541A (en) 1995-07-21 2000-12-05 The Board Of Regents Of The University Of Nebraska Compositions and methods for catalyzing hydrolysis of HIV gp120
US6235714B1 (en) * 1998-03-23 2001-05-22 Sudhir Paul Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
US6855804B2 (en) * 1998-03-23 2005-02-15 Board Of Regents, The University Of Texas System Covalently reactive transition state analogs and methods of use thereof
WO1999063981A2 (en) * 1998-06-11 1999-12-16 Cerus Corporation Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
WO2001017568A2 (en) * 1999-09-07 2001-03-15 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
EP1373307A4 (en) * 2001-03-31 2006-01-25 Univ Texas COVALENT-REACTIVE TRANSITIONAL ANALOGUE AND METHOD OF USE THEREOF
CA2520381A1 (en) 2003-03-26 2004-10-14 Sudhir Paul Proteolytic and covalent antibodies
WO2004087059A2 (en) 2003-03-26 2004-10-14 The University Of Texas Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding
EP1613643A4 (en) 2003-03-27 2009-10-28 Sudhir Paul LUPUS ANTIBODIES FOR THE PASSIVE IMMUNE THERAPY OF HIV / AIDS
BRPI0718698A2 (pt) * 2006-11-09 2013-12-31 Paul Sudhir Anticorpos de epítopo binário e estimulantes imunes de superantígeno de célula b.
US9969797B2 (en) * 2008-04-23 2018-05-15 Covalent Bioscience Incorporated Immunoglobulins directed to bacterial, viral and endogenous polypeptides
WO2012009709A1 (en) * 2010-07-16 2012-01-19 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions

Also Published As

Publication number Publication date
JP5827003B2 (ja) 2015-12-02
EP1610808A4 (en) 2011-04-06
US20070179083A1 (en) 2007-08-02
JP2007527373A (ja) 2007-09-27
JP5503837B2 (ja) 2014-05-28
JP2011105724A (ja) 2011-06-02
WO2004087059A2 (en) 2004-10-14
EP1610808A2 (en) 2006-01-04
WO2004087059A3 (en) 2005-07-21
US9006388B2 (en) 2015-04-14
CA2520392A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
JP5827003B2 (ja) 非共有結合により誘導される求核性タンパク質へのリガンドの共有結合
Andrabi et al. Strategies for a multi-stage neutralizing antibody-based HIV vaccine
McGaughey et al. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb
US10421789B2 (en) Engineered outer domain (EOD) of HIV GP120 and mutants thereof
EP2442829B1 (en) Structured viral peptide compositions and methods of use
JP2023524054A (ja) ベータコロナウイルスの予防と治療
He et al. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci
EP1615946B1 (en) Proteolytic and covalent antibodies
Paul et al. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120
JP7677953B2 (ja) 前立腺癌処置のための免疫治療薬
AU2003214044B2 (en) Anti-idiotypic antibody inducing HIV-1 neutralizing antibodies
Fiorentini et al. Preclinical studies on immunogenicity of the HIV‐1 p17‐based synthetic peptide AT20‐KLH
JPH07505878A (ja) Ｈｉｖエンベロープ糖タンパク質から誘導された合成ポリペプチド
US20090117115A1 (en) Binary epitope antibodies and B cell superantigen immune stimulants
CN112512552A (zh) 自组装肽支架
Nishiyama et al. Towards covalent vaccination: improved polyclonal HIV neutralizing antibody response induced by an electrophilic gp120 V3 peptide analog
IL122443A (en) Synthetic peptides for the treatment of myasthenia gravis and pharmaceutical compositions comprising them
US20100104580A1 (en) Altered Immunogenic Landscape in HIV-1 Envelope Proteins
Kelker et al. Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide.
Planque Antibody chemical reactivity: Beneficial and pathogenic roles
AN Towards Covalent Vaccination
Tretiakova et al. A rational design approach for developing immunomodulators based on CD4 and CD8

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220328